Early Phase 1 Chronic Kidney Disease Trial, Recruiting NCT07577817 Sponsor: Cajal Therapeutics Inc. Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Early Phase 1 Chronic Kidney Disease Trial, Recruiting

NCT07577817
Recruiting Early Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to give their informed consent to participate
  • People who agree to use effective contraception during the trial
  • People whose Body Mass Index (BMI) falls between 18.0 and 32.0
  • People who are considered healthy based on a medical check-up and medical history
  • People whose blood counts, iron levels, and related measures (including transferrin and ferritin) all fall within normal ranges, and whose transferrin saturation is normal and at least 20% (confirm with trial site)
  • People who are able to swallow tablets and have veins that are suitable for taking blood samples

Who may not be able to join:

  • People who have special dietary requirements that may be difficult to accommodate during the trial
  • People who regularly use cannabis, or who have a history of illegal drug use within the past year
  • People who have a history of alcohol abuse or binge drinking within the past 6 months
  • People who regularly use tobacco or any products containing nicotine
  • People who are unwilling or unable to follow the lifestyle guidelines set out in the trial protocol
  • People who have a significant medical history or current condition affecting the heart, lungs, liver, kidneys, digestive system, hormones, nerves, immune system, or mental health, as determined by the trial doctor
  • People who have any other disease, condition, or personal circumstance that the trial doctor considers would make participation unsuitable
  • People who have received a blood transfusion within the past year
  • People who have donated whole blood within the past 6 months, or donated plasma within the past 30 days
  • People who require prescription medicines or who regularly take non-prescription medicines
  • People who are employees of the trial sponsor, the research organisation running the trial, or any site involved in the study, or who are an immediate family member of someone employed at a trial site in a role connected to the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Aarthy Joseph, Dr, Nucleus Network

Phone: +61 07 3707 2787

Australian sites

Nucleus Network, Melbourne, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Cajal Therapeutics Inc.
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 October 2026

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of Participants with Treatment-Emergent Adverse Events (TEAEs); Number of Participants with Serious TEAEs; Number of Participants with Clinically Significant Changes in Physical Examination; Number of Participants with Clinically Significant Changes in Safety Laboratory Values; Number of Participants with Clinically Significant Changes in Vital Signs; Number of Participants with Clinically Significant Changes in Electrocardiograms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov